Correction to: Oncogene (2015) 34, 2505–2515; doi:10.1038/onc.2014.184; published online 7 July 2014
Since the publication of the above paper, the authors found a misplacing band in Figure 2e. The correct version of the figure is given below. The correction does not affect the validity of the data presented and does not limit the conclusions drawn in the paper. The authors apologize for this mistake.
Additional information
The online version of the original article can be found at 10.1038/onc.2014.184
Rights and permissions
About this article
Cite this article
Wu, DW., Lee, MC., Hsu, NY. et al. Erratum: FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. Oncogene 34, 3882–3883 (2015). https://doi.org/10.1038/onc.2015.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.203
This article is cited by
-
CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer
Cell Death & Disease (2019)
-
The diacylglycerol kinase α (DGKα)/Akt/NF-κB feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner
Oncogene (2019)
-
Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT
Cell Death & Disease (2018)
-
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Nature Reviews Clinical Oncology (2017)
-
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
Tumor Biology (2016)